American Regent

Highly Engaged Employees

American Regent, Inc., a subsidiary of the Daiichi Sankyo Group, is a prominent player in the pharmaceutical and healthcare sectors, specializing in the development, manufacturing, and supply of high-quality sterile injectables. Founded in 1999, the company serves healthcare providers, clinics, and hospitals across the United States and Canada. Its product portfolio includes a range of generic and therapeutic injectable medications for human and veterinary use, such as Adequan. American Regent's commitment to quality and accessibility in critical pharmaceutical supplies positions it as a key entity within the industry.

Operating with a dedicated team, American Regent maintains a significant operational footprint. The company employs between 500 - 1,000 employees and manages six distinct locations across New York, Ohio, and Pennsylvania, complemented by nationwide sales territories. This infrastructure supports its extensive product distribution and service capabilities. For insights into the personnel driving its operations, one can explore Meet American Regent's team. The company's strategic presence and robust operational framework enable it to meet the complex demands of the healthcare supply chain effectively.

With an annual revenue of $321.7M, American Regent competes in a dynamic market against established entities like Amphastar Pharmaceuticals, Exela Pharma Sciences, and its parent company, Daiichi Sankyo. Its product offerings, including various injectable medications and therapeutic agents, cater to critical medical needs. The company's market position is further defined by its focus on sterile injectables, a specialized segment within the broader pharmaceutical landscape. Its competitive landscape includes numerous specialized pharmaceutical manufacturers and suppliers, highlighting the intricate nature of the healthcare market.